Fujisawa Pharmaceutical Company, Ltd.

Morishita Jintan Co., Ltd.

Teijin Limited

Takehisa Hata

Saburo Murata

Sumihisa Kimura

Yuji Tokunaga

Akira Kagayama

Sachiyo Tanimoto

Satoshi Ueda

Kazutake Kado

Fumio Shimojo

Sotoo Asakura

Yoshio Ueda

Takashi Morishita

Toshiyasu Honbo

Fumio Shiomojo

Yuji Makino

Atsuo Hazato

Takao Yamamoto

Rinta Ibuki

Kyoko Ishii

Yoshiharu Tsuji

Takeo Hirose

Akihiro Ishino

Seiji Sawai

Toshiyuki Suzuki

Yasuto Koyama

Youhei Kiyota

Hiroshi Ishikuro

Hisami Yamaguchi

Nobuaki Hanajima

Mitsuru Yasumura

Nobuto Kanagawa

Tamotsu Koyama

Shohachi Tanoue

Kenichi Nishimura

Masateru Kodani

Toshiaki Takeda

Hiromitsu Yoshida

Yoshiko Ohishi

Mitio Mori

Atsunori Kaibara

Aerosol compositions

The use of a medium-chain fatty acid triglyceride as the dispersant in the preparation of a medicinal aerosol composition comprising tricyclic compound (I) dispersed in a liquefied hydrofluoroalkane propellant is described. When a liquefied hydrofluoroalkane is added to a kneaded premix of the tricyclic compound (I) and a medium-chain fatty acid triglyceride, the active ingredient is evenly dispersed in the liquefied hydrofluoroalkane. Therefore, by distributing a dispenser first with the kneaded premix and, then, with a liquefied hydrofluoroalkane under cooling or elevated pressure, there can be provided a medicinal aerosol composition having an improved uniformity of content of the active ingredient.

To provide a pharmaceutical composition comprising a water-insoluble active substance, surfactant(s) and solid carrier(s), which is improved in dissolution and oral absorption characteristics.

Medicinal composition

A lotion comprising a tricyclic compound, typically 17-allyl-1,14-dihydroxy-12-�2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l!-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo �22.3.1.0.sup.4,9 !octacos-18-ene-2,3,10,16-tetraone, or a pharmaceutically acceptable salt thereof, a solubilizing and/or absorption-promoting agent, a liquid medium, and optionally an emulsifier and/or a viscosity increasing agent. The lotion is stable, excellent in absorption and has less irritation against the skin and sustained release. Also, the lotion is effective for the treatment and/or prophylaxis of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses.

Lotion for FK 506

A liposome preparation containing an immunosuppresive tricylic compound or a pharmaceutically acceptable salt thereof. Since the tricyclic compound is entrapped stably and quantitatively into the liposomes, a broad variety of drug forms and pharmaceutical preparations insuring a long duration of efficacy can be provided.

Liposome preparation containing a tricyclic compound

This invention relates to an aqueous liquid composition for external use which contains a tricyclo compound of the chemical formula (I) presented here-under or a pharmaceutically acceptable salt thereof. More particularly, the invention relates to an aqueous liquid composition for external use characterized in that it contains said tricyclo compound and a water-soluble solubilizer. The composition of the invention is used in medical treatment.

Aqueous liquid composition for external use

Percutaneously absorbable preparation

Encapsulated medicine

External skin treatment agent composition containing isocarbacyclins as

The invention relates to a delayed action preparation which comprises a core comprising a drug and a swelling agent and an outer membrane comprising a biodegradable high molecular weight substance characterized in that the swelling agent is contained in a sufficient amount to cause a explosion of the outer membrane of biodegradable high molecular weight substance at a definite time after administration. This preparation provides for free control over the timing of drug release and is suited for administration not only by the oral route but also by the intramuscular, subcutaneous and other routes.

Delayed action preparation

Sustained release medicinal preparation

A hair revitalizing agent including a compound represented by the formula shown below or a pharmaceutically acceptable salt thereof: ##STR1## (wherein R.sup.1 to R.sup.10, R.sup.14 to R.sup.23, X, Y, and n are the same as defined in the present specification).

Hair revitalizing agent

The present invention relates to liposome preparations. In particular, the present invention relates to Adriamycin-entrapped liposome preparations comprising cholesterol derivatives having a negative charge as a liposome membrane constituent. Adriamycin-entrapped liposome preparations have many uses in the medical field such as maintaining high Adriamycin blood levels over a long period of time and reducing systemic toxicity, for example.

Liposome preparation

The present invention relates to a pharmaceutical composition for percutaneous drug absorption which comprises 5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and ethanol and/or an unsaturated higher fatty acid and to a composition of matter which comprises ethanol and/or an unsaturated higher fatty acid and is capable of promoting percutaneous absorption of said dihydropyridine compound.

Pharmaceutical composition for percutaneous drug absorption and

The invention relates to a Time-Controlled Explosion System in which drug release is caused by explosion of a membrane after a definite time period, said System comprising a preparation in the form of a bead or granule, said preparation comprising a core, a drug, swelling agent and an outer membrane of water-insoluble coating material.

Time-controlled explosion systems and processes for preparing the same

Growing community of inventors

Nagaokakyo, Japan

Takehisa Hata